Protocol summary
-
Study aim
-
Crestor 5 mg tablet of Astra-Zeneca can be changed by Aristatin 5 mg tablet of Arya Pharm Co., IRAN?
-
Design
-
An open label, two treatments, two periods, single dose, crossover, bioequivalence study of Aristatin 5 mg tablet of Arya Pharm Co., IRAN in comparison of Crestor 5 mg tablet of Astra-Zeneca in 24 healthy subjects under fasting condition
-
Settings and conduct
-
Sampling center: Core Research Lab. of Zahedan University of Medical Sciences
Method of sampling:
1- Subject no. and condition: 24 healthy subjects
2- Dose & administration: A single dose of 2*5 mg rosuvastatin under fasting condition
3-Sampling time: before and at 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 24.0 & 48.0 hr. post-dose.
4- Period of treatment phases: two times separate by a washout period of at least 7 days.
5- Method analysis of rosuvastatin in the plasma: HPLC.
-
Participants/Inclusion and exclusion criteria
-
Main Inclusion criteria: Healthy subjects aged between 18 -50 years old and weighted between 50 – 100 kg\\ Main exclusion criteria: Clinically relevant deviations from normal; Donation a unit of blood or participated in another clinical trial within the last three months; History of drug or alcohol abuse ; Used any medication within 7- 14 days before the first treatment; History of allergic to statins
-
Intervention groups
-
Intervention: single dose of Aristatin 5 mg tablet of Arya Pharm Co., IRAN Control: single dose of Crestor 5 mg tablet of Astra-Zeneca
-
Main outcome variables
-
Plasma concentration of rosuvastatin
General information
-
Reason for update
-
This Study was cancelled by sponsor (Arya Pharm. Co.).
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20190706044111N12
Registration date:
2019-11-10, 1398/08/19
Registration timing:
prospective
Last update:
2021-06-03, 1400/03/13
Update count:
1
-
Registration date
-
2019-11-10, 1398/08/19
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2019-11-22, 1398/09/01
-
Expected recruitment end date
-
2020-06-20, 1399/03/31
-
Actual recruitment start date
-
empty
-
Actual recruitment end date
-
empty
-
Trial completion date
-
empty
-
Scientific title
-
An open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Aristatin 5 mg tablet of Arya Pharm Co., IRAN and Crestor 5 mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition
-
Public title
-
Bioequivalence study of Aristatin 5 mg tablet of Arya Pharm
-
Purpose
-
Other
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
- Aged between 18 - 50 years
- Body weight between 50 – 100 kg
- Having good health on the basis of medical history and physical & clinical examination
- Understand the procedures and give written informed consent
Exclusion criteria:
Subject showed clinically relevant deviations from normal in physical examination.
Subject had undergone surgery of the gastro-intestinal tract
Subject had donated a unit of blood or participated in another clinical trial, within the last three months before the first treatment
Subject had a history of drug or alcohol abuse.
Subject who smokes more than 10 cigarettes per day.
Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.
Subject had a history of allergic to statins
-
Age
-
From 18 years old to 50 years old
-
Gender
-
Both
-
Phase
-
Bioequivalence
-
Groups that have been masked
-
No information
-
Sample size
-
Target sample size:
24
More than 1 sample in each individual
Number of samples in each individual:
2
Each volunteer, 2 times take medicine in the study. One time test product and the other time reference product with at least one week wash-out period.
-
Randomization (investigator's opinion)
-
Not randomized
-
Randomization description
-
-
Blinding (investigator's opinion)
-
Not blinded
-
Blinding description
-
-
Placebo
-
Not used
-
Assignment
-
Crossover
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2018-09-02, 1397/06/11
-
Ethics committee reference number
-
IR.SBMU.RETECH.REC.1397.359
Health conditions studied
1
-
Description of health condition studied
-
Hyperlipidemia
-
ICD-10 code
-
-
ICD-10 code description
-
Primary outcomes
1
-
Description
-
Plasma concentration of rosuvastatin
-
Timepoint
-
At 0 (before dosing), 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 24.0 & 48.0 hr. after dosing
-
Method of measurement
-
HPLC
Intervention groups
1
-
Description
-
Intervention group: Single dose of Aristatin 5 mg tablet of Arya Pharm Co., IRAN
-
Category
-
Other
2
-
Description
-
Control group: Single dose of Crestor 5 mg tablet of Astra-Zeneca
-
Category
-
Other
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Arya Pharm Company
-
Proportion provided by this source
-
100
-
Public or private sector
-
Private
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Industry
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available